means that certain fully human, IgG4 isotype antibody which
binds to human PD-1 with high affinity and inhibits the interaction of PD-1 to
both PD-L1 and PD-L2 that, as of the Execution Date, is the subject of multiple
clinical trials by Arcus exploring safety as well as pharmacokinetic (PK) and
pharmacodynamics (PD) readouts.
Each of the following terms is defined in the Section set forth opposite such
term:
Term
Section
Agreement
Preamble
Alliance Manager
2.9
Anti-Corruption Laws
11.1(e)
Antitrust Clearance Date
16.1(b)
Approved Acquired Product
3.3(c)(iii)
Arcus
Preamble
Arcus Collaboration IP
10.1(a)
Arcus Collaboration Know-How
10.1(a)
Arcus Collaboration Patents
10.1(a)
Arcus Indemnitees
12.2
Arcus Independent Activities
4.8(a)
Arcus Independent Activities Costs
4.8(e)
Arcus Independent Activities Data
4.8(d)(i)
20
--------------------------------------------------------------------------------
Term
Section
Arcus Independent Activities Plan and Budget
4.8(b)(i)
Arcus Independent Activities Regulatory Documentation
4.8(d)(ii)
Arcus Independent Activities [***] Amount
4.8(e)
Arcus Program Period
8.3(a)
Arcus Prosecution Countries
10.2(b)(iv)
Arcus R&D Activities
3.1
Arcus ROFN Negotiation Notice
8.7(c)
Arcus ROFN Negotiation Period
8.7(c)
Arcus ROFN Notice
8.7(c)
Arcus ROFN Notification Period
8.7(c)
Arcus Schedule of Exceptions
11.2
Bankruptcy Code
14.6
Baseline Budget Period
1.14
Bribery Act
11.1(e)
Clinical Supply Agreement
7.2(d)
CMC Plan and Budget
7.1
Combination Development Plan
3.5(c)(i)(B)
Commercial Supply Agreement
7.2(e)
Commercialization Plan and Budget
6.2(b)
Committee Dispute
15.1(c)
Confidential Information
13.1(a)
Confirmed Arcus Program
3.3(e)(i)
Co-Promotion Product
5.2(a)
Co-Promotion Agreement
5.2(a)
Dispute
15.1(b)
DOJ
8.3(d)(ii)
Enforcing Party
10.5(f)
Execution Date
Preamble
FCPA
11.1(e)
FTC
8.3(d)(ii)
Finance Officer
9.11(b)(i)
Gilead
Preamble
Gilead Clinical Trial
14.7(c)(iv)(A)
Gilead Collaboration IP
10.1(b)
Gilead Contributions
3.2
Gilead IND
5.2(c)
Gilead Indemnitees
12.1
Gilead Reversion Know-How
14.7(c)(i)
Gilead Reversion Patents
14.7(c)(i)
Global Manufacturing Plan and Budget
7.2(a)
21
--------------------------------------------------------------------------------
Term
Section
ICC Rules
15.2(c)
Included Net Sales
9.5(a)
Indemnified Party
12.3
Indemnifying Party
12.3
Infringing Activity
10.7(a)
Initial Option Closing
8.3(c)(i)
Investor Rights Agreement
Preamble
Joint Collaboration IP
10.1(c)
Joint Development Committee or JDC
2.2(a)
Joint Steering Committee or JSC
2.1(a)
Losses
12.1
Material Adverse Effect
11.2(s)
Medical Affairs Plan and Budget
6.6
Non-Committee Dispute
15.1(b)
Non-Enforcing Party
10.5(f)
[***]
6.2(a)
Option
8.3(a)
Option Bringdown Date
8.3(c)(ii)
Option Continuation Payment
9.3
Option Exercise Closing
8.3(c)(i)
Option Exercise Notice
8.3(b)(i)
Option Exercise Period
8.3(b)(i)
Option Payment
9.2
Optioned Product Orange Book Listing
10.4
Optioned Program R&D Activities
4.2
Opt-Out Notice
4.7(a)
Outside Date
14.2
Confirmed Arcus Program
3.3(e)(i)
Party or Parties
Preamble
Party Indemnitees
12.4(a)
Patent Challenge
14.4
Patent Litigation Committee
10.5(b)
Patent Prosecution Committee
10.2(a)
Patent Term Extensions
10.3
Personal Information
11.2(n)(iii)
Post-Option In-License
9.7(b)
Program Infringement
10.5(a)
Profit Payment Report
9.11(b)(ii)
[***]
1.159
Proposal
15.2(d)(i)
Prosecution
10.2(b)(i)
Publication
13.4(a)(i)
22
--------------------------------------------------------------------------------
Term
Section
PV Agreement
5.2(g)(i)
[***]
1.160
[***]
1.159
[***]
9.12(a)
Redacted Agreements
13.3(c)
Regulatory Transition Date
5.2(b)(i)(D)
Representatives
11.1(e)
Royalties
9.5(a)
Royalty Term
9.5(b)
Samples
4.10
Second Request
8.3(d)(ii)
Shared Commercialization Claims
12.5(a)
Shared Commercialization Losses
12.5(a)
Shared Development Claims
12.4(a)
Shared Development Losses
12.4(a)
Shared Patent Costs
9.14(a)
Sublicensing Party
8.7(b)
Stock Purchase Agreement
Preamble
TCT Criteria
8.3(b)(vii)
TCT Determination Package
3.3(c)(i)
Technology Transfer
7.3(b)
Technology Transfer Plan
7.3(b)